Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection
| Autor: | D M Higgins, Bruce Montgomery, J P Borwell |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal Visual analogue scale Urology Pain Prostate cancer Leuprorelin Patient experience medicine Humans Single-Blind Method Clinical significance Aged Pain Measurement Aged 80 and over Luteinising hormone releasing hormone business.industry Goserelin Prostatic Neoplasms Middle Aged medicine.disease Surgery Needle size Oncology Needles Patient Satisfaction Leuprolide business medicine.drug |
| Zdroj: | Prostate Cancer and Prostatic Diseases. 8:66-68 |
| ISSN: | 1476-5608 1365-7852 |
| DOI: | 10.1038/sj.pcan.4500778 |
| Popis: | To determine whether needle size influences a patient's perception of pain, 50 patients requiring hormonal manipulation for prostate cancer were blindfolded and randomised to receive two goserelin ('Zoladex') or two leuprorelin ('Prostap') injections, using 16- or 23-gauge needles, respectively. Median visual analogue scale pain scores for the first injections of goserelin and leuprorelin were below the level of clinical significance and were not statistically different. Mean administration time for goserelin was significantly shorter than for leuprorelin. In conclusion, there was no statistically significant difference in pain experienced on injection of goserelin and leuprorelin when patients were unaware of needle size. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|